Hims & Hers Health, Inc.

HIMS Healthcare Drug Manufacturers Specialty & Generic

Hims & Hers Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 59.0% from fiscal 2024.

Revenue
+38.3%
EPS
−294.7%
Free cash flow
+5.09%
Total debt
+40.8%

Quarter to June 2026, against a year earlier

25.43 1.37 +5.69%
Market cap
$5.6B
P/E
0.0×
Fwd P/E
−49.4×
Dividend yield
—
F-score
4/9
Altman Z
4.10
Beneish M
n/a
Dividend safety
n/a

Hims & Hers Health, Inc. 10-Q filed May 11, 2026

Fiscal Q1 2026 · Period ended Mar 31, 2026 · Filed · accepted 4:15 PM ET · Document on sec.gov · Filing index

Nothing in this filing raised a red flag. The document itself is on sec.gov.

Read the filing on sec.gov